OPEN Health and Nested Knowledge announce strategic research collaboration to leverage AI technologies for evidence synthesis
11 déc. 2023 04h00 HE
|
Open Health
London, Dec. 11, 2023 (GLOBE NEWSWIRE) -- London, UK – December 11, 2023 – OPEN Health, a preeminent global provider of consulting, HEOR and market access, patient engagement, and scientific and...
Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients
01 nov. 2022 07h00 HE
|
Gb Sciences
LAS VEGAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the...
Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease
10 oct. 2022 07h00 HE
|
Gb Sciences
LAS VEGAS, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the...
TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit
12 mai 2022 09h00 HE
|
Gb Sciences
LAS VEGAS, May 12, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and...
TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference
05 mai 2022 09h30 HE
|
Gb Sciences
LAS VEGAS, May 05, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and...
FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies
02 mai 2022 09h00 HE
|
Gb Sciences
LAS VEGAS, May 02, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, announces that FHI Clinical Inc. will...
Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge
12 avr. 2022 09h00 HE
|
Gb Sciences
LAS VEGAS, April 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, has selected the University of Lethbridge...
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article
29 mars 2022 08h00 HE
|
Gb Sciences
LAS VEGAS, March 29, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired, biopharmaceutical research and development company, announces that their...
UPDATE: Gb Sciences Issues Shareholder Letter
16 mars 2022 15h01 HE
|
Gb Sciences
LAS VEGAS, March 16, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, today issued a letter to...
Gb Sciences Issues Summary Shareholder Letter
15 mars 2022 07h00 HE
|
Gb Sciences
LAS VEGAS, March 15, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, today issued a letter to...